All In Biotech

Drug Trial Radar · NCT04519658

A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Multiple Dose Strengths of CIN-107 as Compared to Placebo After 12 Weeks of Treatment in Patients With Treatment-Resistant Hypertension (rHTN)

Last checked: Nov 20, 2026Latest source record: Jul 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 275 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

275

Actual

Start

Oct 12, 2020

Primary completion

Jun 14, 2022

Study completion Jun 14, 2022

Sponsor

Lead sponsor
CinCor Pharma, Inc.Industry
Sponsor type
Industry
First posted
Aug 20, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study to evaluate the efficacy and safety of CIN-107 as compared to placebo after 12 weeks of treatment in patients with treatment-resistant hypertension (rHTN).

Conditions

  • Resistant Hypertension

Interventions

  • CIN-107Drug

    CIN-107 tablets by mouth once daily

  • PlaceboDrug

    placebo tablets by mouth once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Mean Seated Systolic BP (SBP)Time frame: 12 weeks

Locations

80 sites in 1 country. Site status is shown where the registry gives one.

  • CinCor Site 16

    Birmingham, Alabama

  • CinCor Site 38

    Birmingham, Alabama

  • CinCor Site 61

    Saraland, Alabama

  • CinCor Site 90

    Tucson, Arizona

  • CinCor Site 82

    Anaheim, California

  • CinCor Site 91

    Granada Hills, California

  • CinCor Site 25

    Lincoln, California

  • CinCor Site 73

    Los Angeles, California

  • CinCor Site 36

    Los Angeles, California

  • CinCor Site 34

    Lynwood, California

  • CinCor Site 14

    San Dimas, California

  • CinCor Site 28

    Santa Ana, California

  • CinCor Site 19

    Spring Valley, California

  • CinCor Site 32

    Tustin, California

  • CinCor Site 44

    West Hills, California

  • CinCor Site 66

    Whittier, California

  • CinCor Site 56

    Stamford, Connecticut

  • CinCor Site 30

    Clearwater, Florida

  • CinCor Site 13

    Fort Myers, Florida

  • CinCor Site 74

    Hialeah, Florida

  • CinCor Site 22

    Homestead, Florida

  • CinCor Site 20

    Jacksonville, Florida

  • CinCor Site 1

    Jupiter, Florida

  • CinCor Site 84

    Lake Worth, Florida

  • CinCor Site 70

    Miami, Florida

  • CinCor Site 89

    Miami, Florida

  • CinCor Site 94

    Miami, Florida

  • CinCor Site 5

    Port Orange, Florida

  • CinCor Site 9

    St. Petersburg, Florida

  • CinCor Site 23

    Tampa, Florida

  • CinCor Site 88

    Winter Haven, Florida

  • CinCor Site 71

    Suwanee, Georgia

  • CinCor Site 11

    Meridian, Idaho

  • CinCor Site 15

    Addison, Illinois

  • CinCor Site 81

    Arlington Heights, Illinois

  • CinCor Site 49

    Chicago, Illinois

  • CinCor Site 35

    Morton, Illinois

  • CinCor Site 58

    Evansville, Indiana

  • CinCor Site 54

    West Des Moines, Iowa

  • CinCor Site 29

    Lexington, Kentucky

Showing 40 of 80 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.